Puma Biotechnology Inc (PBYI) Receives $130.67 Average PT from Brokerages
Puma Biotechnology Inc (NASDAQ:PBYI) has been given an average recommendation of “Buy” by the eleven analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $130.67.
PBYI has been the topic of a number of research reports. BidaskClub upgraded shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 31st. J P Morgan Chase & Co reiterated a “buy” rating on shares of Puma Biotechnology in a research note on Tuesday, August 1st. Leerink Swann restated an “outperform” rating and set a $125.00 price target on shares of Puma Biotechnology in a research report on Wednesday, August 2nd. Stifel Nicolaus restated a “buy” rating and set a $110.00 price target (down previously from $118.00) on shares of Puma Biotechnology in a research report on Thursday, August 10th. Finally, Barclays PLC assumed coverage on shares of Puma Biotechnology in a research report on Wednesday, September 6th. They set an “overweight” rating and a $103.00 price target on the stock.
Puma Biotechnology (PBYI) traded down $0.75 during trading hours on Thursday, hitting $101.65. 277,054 shares of the stock were exchanged, compared to its average volume of 1,009,659. Puma Biotechnology has a 1 year low of $28.35 and a 1 year high of $136.90.
Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.50) by $0.43. The business had revenue of $6.10 million during the quarter, compared to analyst estimates of $3.78 million. During the same quarter in the previous year, the company earned ($1.11) EPS. research analysts forecast that Puma Biotechnology will post -8.19 EPS for the current fiscal year.
In related news, SVP Richard Paul Bryce sold 15,000 shares of the firm’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $120.00, for a total transaction of $1,800,000.00. Following the sale, the senior vice president now owns 42,239 shares in the company, valued at $5,068,680. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 21.10% of the stock is currently owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in PBYI. Bank of Montreal Can lifted its holdings in Puma Biotechnology by 1.8% during the second quarter. Bank of Montreal Can now owns 5,351 shares of the biopharmaceutical company’s stock valued at $468,000 after purchasing an additional 97 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in Puma Biotechnology by 5.9% during the second quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 140 shares in the last quarter. Legal & General Group Plc lifted its holdings in Puma Biotechnology by 2.8% during the first quarter. Legal & General Group Plc now owns 9,297 shares of the biopharmaceutical company’s stock valued at $346,000 after purchasing an additional 249 shares in the last quarter. Rhumbline Advisers lifted its holdings in Puma Biotechnology by 0.8% during the second quarter. Rhumbline Advisers now owns 33,733 shares of the biopharmaceutical company’s stock valued at $2,948,000 after purchasing an additional 271 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in Puma Biotechnology by 2.0% during the second quarter. The Manufacturers Life Insurance Company now owns 22,299 shares of the biopharmaceutical company’s stock valued at $1,950,000 after purchasing an additional 437 shares in the last quarter. Institutional investors own 91.61% of the company’s stock.
WARNING: This story was published by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.watchlistnews.com/puma-biotechnology-inc-pbyi-receives-130-67-average-pt-from-brokerages/1728013.html.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.